{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:00:12Z","timestamp":1780725612865,"version":"3.54.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>LL2, an anti-CD22 monoclonal antibody against B-cell lymphoma, was covalently linked to the amphibian ribonuclease, onconase, a member of the pancreatic RNase A superfamily. LL2 increased in vitro potency (10\u2009000-fold) and specificity against human Daudi Burkitt lymphoma cells while decreasing systemic toxicity of onconase. Monensin further increased potency of LL2-onconase on Daudi cells (IC50, 20 and 1.5 pM, absence and presence of monensin, respectively). A 1-hour exposure to LL2-onconase was sufficient to kill Daudi cells in culture. These favorable in vitro properties translated to significant antitumor activity against disseminated Daudi lymphoma in mice with severe combined immunodeficiency disease. In mice inoculated with tumor cells intraperitoneally (ip), LL2-onconase (100 \u03bcg 5 times ip every day) increased the life span of animals with minimal disease 200%. The life span of mice with advanced disseminated Daudi lymphoma (tumor cells inoculated intravenously) was increased 135%. Mice injected with LL2-onconase tolerated a dose as high as 300 mg\/kg. Because both onconase and LL2 are in clinical trials as cancer therapeutics, the covalently linked agents should be considered for treatment of non-Hodgkin lymphoma.<\/jats:p>","DOI":"10.1182\/blood.v97.2.528","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"528-535","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Potent and specific antitumor effects of an anti-CD22\u2013targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"97","author":[{"given":"Dianne L.","family":"Newton","sequence":"first","affiliation":[{"name":"1 From the SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD; Immunomedics Inc, Morris Plains NJ; Alfacell Corp, Bloomfield, NJ; Garden State Cancer Center, Belleville, NJ; and Pharmaceutical Experimental Therapeutics Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hansen","sequence":"additional","affiliation":[{"name":"1 From the SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD; Immunomedics Inc, Morris Plains NJ; Alfacell Corp, Bloomfield, NJ; Garden State Cancer Center, Belleville, NJ; and Pharmaceutical Experimental Therapeutics Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislaw M.","family":"Mikulski","sequence":"additional","affiliation":[{"name":"1 From the SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD; Immunomedics Inc, Morris Plains NJ; Alfacell Corp, Bloomfield, NJ; Garden State Cancer Center, Belleville, NJ; and Pharmaceutical Experimental Therapeutics Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"1 From the SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD; Immunomedics Inc, Morris Plains NJ; Alfacell Corp, Bloomfield, NJ; Garden State Cancer Center, Belleville, NJ; and Pharmaceutical Experimental Therapeutics Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna M.","family":"Rybak","sequence":"additional","affiliation":[{"name":"1 From the SAIC Frederick, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD; Immunomedics Inc, Morris Plains NJ; Alfacell Corp, Bloomfield, NJ; Garden State Cancer Center, Belleville, NJ; and Pharmaceutical Experimental Therapeutics Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020071613150571100_B1","first-page":"S19","article-title":"Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates.","volume":"4","author":"Press","year":"1998","journal-title":"Cancer J Sci Am."},{"key":"2020071613150571100_B2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0008-8749(89)90359-6","article-title":"The eptitope and tissue reactivity of four murine monoclonal anti-CD22 antibodies.","volume":"118","author":"Li","year":"1989","journal-title":"Cell Immunol."},{"key":"2020071613150571100_B3","first-page":"4568","article-title":"Two new monoclonal antibodies, EPB-1 and EPB-2 reactive with human lymphoma.","volume":"49","author":"Pawlak-Byczkowska","year":"1989","journal-title":"Cancer Res."},{"key":"2020071613150571100_B4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF01518451","article-title":"Epitope specificity of the anti-B-cell lymphoma monoclonal antibody, LL2.","volume":"37","author":"Stein","year":"1993","journal-title":"Cancer Immunol Immunother."},{"key":"2020071613150571100_B5","first-page":"104","article-title":"CD22-directed immunotherapy of NHL with Epratuzumab results in objective responses with minimal toxicity.","volume":"15","author":"Leonard","year":"2000","journal-title":"Cancer Biother Radiopharm."},{"key":"2020071613150571100_B6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/scbi.1995.0038","article-title":"Targeting Pseudomonas exotoxin to hematologic malignancies.","volume":"6","author":"Kreitman","year":"1995","journal-title":"Cancer Biol."},{"key":"2020071613150571100_B7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev.immunol.14.1.49","article-title":"Immunotoxins: an update.","volume":"14","author":"Thrush","year":"1996","journal-title":"Ann Rev Immunol."},{"key":"2020071613150571100_B8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10428199509059607","article-title":"Immunotoxins for treatment of leukemia and lymphoma.","volume":"18","author":"Uckun","year":"1995","journal-title":"Leuk Lymphoma."},{"key":"2020071613150571100_B9","first-page":"2610","article-title":"Evaluation of ricin A-chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.","volume":"48","author":"Ghetie","year":"1988","journal-title":"Cancer Res."},{"key":"2020071613150571100_B10","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood.V84.3.702.702","article-title":"The anti-tumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.","volume":"84","author":"Ghetie","year":"1992","journal-title":"Blood."},{"key":"2020071613150571100_B11","first-page":"5876","article-title":"Antitumor activity of Fab\u2032 and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease effect on tumor cells in extranodal sites.","volume":"51","author":"Ghetie","year":"1991","journal-title":"Cancer Res."},{"key":"2020071613150571100_B12","first-page":"4052","article-title":"Phase I immunotoxin trial in patients with B-cell lymphoma.","volume":"51","author":"Vitetta","year":"1991","journal-title":"Cancer Res."},{"key":"2020071613150571100_B13","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V82.9.2624.2624","article-title":"A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.","volume":"82","author":"Amlot","year":"1993","journal-title":"Blood."},{"key":"2020071613150571100_B14","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V85.12.3457.bloodjournal85123457","article-title":"Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.","volume":"85","author":"Sausville","year":"1995","journal-title":"Blood."},{"key":"2020071613150571100_B15","doi-asserted-by":"crossref","first-page":"882","DOI":"10.7326\/0003-4819-126-11-199706010-00005","article-title":"Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.","volume":"126","author":"Senderowicz","year":"1997","journal-title":"Ann Intern Med."},{"key":"2020071613150571100_B16","first-page":"819","article-title":"Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab\u2032 induce regression of subcutaneous human B-cell lymphoma in mice.","volume":"53","author":"Kreitman","year":"1993","journal-title":"Cancer Res."},{"key":"2020071613150571100_B17","first-page":"148","article-title":"Immunotoxins: magic bullets or misguided missiles.","volume":"14","author":"Vitetta","year":"1993","journal-title":"TiPS."},{"key":"2020071613150571100_B18","first-page":"53","article-title":"Immunoenzymes.","volume-title":"Antibody Fusion Proteins.","author":"Rybak","year":"1999"},{"key":"2020071613150571100_B19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/excr.1998.4317","article-title":"Cell cycle-related differences in susceptibility of NIH\/3T3 cells to ribonucleases.","volume":"247","author":"Smith","year":"1999","journal-title":"Exp Cell Res."},{"key":"2020071613150571100_B20","first-page":"141","article-title":"RNase and RNase immunofusions for cancer therapy.","volume":"1","author":"Rybak","year":"1995","journal-title":"Tumor Targeting."},{"key":"2020071613150571100_B21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/bi951650w","article-title":"Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.","volume":"35","author":"Newton","year":"1996","journal-title":"Biochemistry."},{"key":"2020071613150571100_B22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/bjc.1998.87","article-title":"Design, characterization and antitumor cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.","volume":"77","author":"Deonarain","year":"1998","journal-title":"Br J Cancer."},{"key":"2020071613150571100_B23","doi-asserted-by":"crossref","first-page":"127136","DOI":"10.1016\/S1380-2933(97)00070-5","article-title":"Cloning and cytotoxicity of a human pancreatic RNase immunofusion.","volume":"3","author":"Zewe","year":"1997","journal-title":"Immunotechnology."},{"key":"2020071613150571100_B24","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/protein\/11.12.1285","article-title":"Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human immunotoxin analog with cytotoxic properties against squamous cell carcinomas.","volume":"11","author":"Psarras","year":"1998","journal-title":"Protein Eng."},{"key":"2020071613150571100_B25","first-page":"1983","article-title":"Molecular determinants of programmed cell death induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis.","volume":"60","author":"Iordanov","year":"2000","journal-title":"Cancer Res."},{"key":"2020071613150571100_B26","first-page":"1257","article-title":"Pathogenesis of cancer in view of mutually opposing apoptotic and anti-apoptotic growth signals.","volume":"4","author":"Milkulski","year":"1994","journal-title":"Int J Oncol."},{"key":"2020071613150571100_B27","first-page":"11","article-title":"Potentiation of tumor necrosis factor induced apoptosis by onconase.","volume":"13","author":"Deptala","year":"1998","journal-title":"Int J Oncol."},{"key":"2020071613150571100_B28","first-page":"57","article-title":"Phase 1 human clinical trial of ONCONASE (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors.","volume":"3","author":"Mikulski","year":"1993","journal-title":"Int J Oncol."},{"key":"2020071613150571100_B29","first-page":"3337s","article-title":"Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.","volume":"5(Suppl)","author":"Juweid","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2020071613150571100_B30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.1991.9.4.548","article-title":"Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.","volume":"9","author":"Goldenberg","year":"1991","journal-title":"J Clin Oncol."},{"key":"2020071613150571100_B31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0889-8561(22)00327-7","article-title":"Clinical use of immunotoxins: monoclonal antibodies conjugated to protein toxins.","volume":"11","author":"Rybak","year":"1991","journal-title":"Immunol Allergy Clin N Am."},{"key":"2020071613150571100_B32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0076-6879(83)91010-8","article-title":"Reassessment of Ellman's reagent.","volume":"91","author":"Riddles","year":"1983","journal-title":"Methods Enzymol."},{"key":"2020071613150571100_B33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/10717549309031335","article-title":"Cytotoxic onconase and ribonuclease A chimeras: comparison and in vitro characterization.","volume":"1","author":"Rybak","year":"1993","journal-title":"Drug Deliv."},{"key":"2020071613150571100_B34","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1021\/bi972147h","article-title":"Single amino acid substitutions at the N-terminus of a recombinant cytotoxic ribonuclease markedly influence biochemical and biological properties.","volume":"37","author":"Newton","year":"1998","journal-title":"Biochemistry."},{"key":"2020071613150571100_B35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ijc.2910450318","article-title":"Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice.","volume":"45","author":"Ghetie","year":"1990","journal-title":"Int J Cancer."},{"key":"2020071613150571100_B36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0021-9258(18)52427-3","article-title":"Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos.","volume":"266","author":"Ardelt","year":"1991","journal-title":"J Biol Chem."},{"key":"2020071613150571100_B37","doi-asserted-by":"crossref","first-page":"21202","DOI":"10.1016\/S0021-9258(18)54841-9","article-title":"Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins.","volume":"266","author":"Rybak","year":"1991","journal-title":"J Biol Chem."},{"key":"2020071613150571100_B38","doi-asserted-by":"crossref","first-page":"19572","DOI":"10.1016\/S0021-9258(18)41813-3","article-title":"Cytotoxic ribonuclease chimeras: targeted tumoricidal activity in vitro and in vivo.","volume":"267","author":"Newton","year":"1992","journal-title":"J Biol Chem."},{"key":"2020071613150571100_B39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4613-1083-9_19","article-title":"Immunotoxin enhancers.","volume-title":"Immunotoxins.","author":"Casellas","year":"1988"},{"key":"2020071613150571100_B40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s002800050962","article-title":"Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake.","volume":"44","author":"Vasandani","year":"1999","journal-title":"Cancer Chemother Pharmacol."},{"key":"2020071613150571100_B41","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1016\/S0021-9258(18)82252-9","article-title":"Cytotoxic ribonuclease: a study of the mechanism of onconase cytotoxicity.","volume":"268","author":"Wu","year":"1993","journal-title":"J Biol Chem."},{"key":"2020071613150571100_B42","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jnci\/88.11.747","article-title":"Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.","volume":"88","author":"Rybak","year":"1996","journal-title":"J Natl Cancer Inst."},{"key":"2020071613150571100_B43","doi-asserted-by":"crossref","first-page":"17476","DOI":"10.1074\/jbc.270.29.17476","article-title":"A study of the intracellular routing of cytotoxic ribonucleases.","volume":"270","author":"Wu","year":"1995","journal-title":"J Biol Chem."},{"key":"2020071613150571100_B44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.leu.2401262","article-title":"Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.","volume":"13","author":"vanHorssen","year":"1999","journal-title":"Leukemia."},{"key":"2020071613150571100_B45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/bc960043y","article-title":"Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.","volume":"7","author":"Mansfield","year":"1996","journal-title":"Bioconjug Chem."},{"key":"2020071613150571100_B46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0192-0561(87)90096-8","article-title":"The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies.","volume":"9","author":"Scott","year":"1987","journal-title":"Int J Immunopharmacol."},{"key":"2020071613150571100_B47","first-page":"151","article-title":"An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome inactivating protein from Saponaria officinalis: potent anti-tumor effects in vitro and in vivo.","volume":"75","author":"Thorpe","year":"1985","journal-title":"J Natl Cancer Inst."},{"key":"2020071613150571100_B48","first-page":"4180","article-title":"Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuclease A superfamily.","volume":"56","author":"Vasandani","year":"1996","journal-title":"Cancer Res."},{"key":"2020071613150571100_B49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0304-3835(95)04001-K","article-title":"The in vivo anti-tumor activity of immunotoxins containing two versus one deglycoslated ricin A chains.","volume":"98","author":"Ghetie","year":"1995","journal-title":"Cancer Lett."},{"key":"2020071613150571100_B50","first-page":"4824","article-title":"Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.","volume":"57","author":"Flavell","year":"1997","journal-title":"Cancer Res."},{"key":"2020071613150571100_B51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/(SICI)1097-0215(19961104)68:3<378::AID-IJC17>3.0.CO;2-4","article-title":"Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice.","volume":"68","author":"Van Horssen","year":"1996","journal-title":"Int J Cancer."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/2\/528\/1590442\/528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/2\/528\/1590442\/528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T20:10:38Z","timestamp":1682280638000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/2\/528\/52833\/Potent-and-specific-antitumor-effects-of-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,15]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.2.528","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,1,15]]}}}